. Author manuscript; available in PMC: 2020 Feb 17.

Published in final edited form as: Biosci Rep. 2012 Apr 1;32(2):113–130. doi: 10.1042/BSR20110046

Table 2.

Overview of FOXA1 in human cancer

Cancer type	FOXA1 expression relative to normal	Predicted activity	Reference(s)
AML	Increased	Oncogenic	[76]
Breast	No difference	Unclear	[64,65,128–132]
	Amplified in ER+/PR+ tumours	Oncogenic	[133]
Oesophageal	Amplified/overexpressed	Oncogenic	[78,79]
HCC	Expressed in favourable prognosis tumours	Tumour suppressive	[85]
Lung	Amplified/overexpressed	Oncogenic	[78]
Pancreatic	Decreased in poorly differentiated disease	Tumour suppressive	[80]
Prostate	No difference	Unclear	[59]
	Decreased in associated metastases/favourable outcome	Tumour suppressive	[110]
	Increased in associated metastases/poor outcome	Oncogenic	[102,103]
	Amplified in associated metastases	Oncogenic	[104]
Thyroid	Amplified/overexpressed	Oncogenic	[77]